Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 12, 2021

SELL
$23.37 - $32.13 $24.7 Million - $34 Million
-1,057,389 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$18.78 - $25.15 $2.04 Million - $2.73 Million
-108,494 Reduced 9.31%
1,057,389 $25.9 Million
Q1 2021

May 13, 2021

SELL
$18.21 - $23.2 $3,459 - $4,408
-190 Reduced 0.02%
1,165,883 $21.8 Million
Q2 2020

Aug 14, 2020

BUY
$13.31 - $19.41 $7,986 - $11,646
600 Added 0.05%
1,166,073 $22.6 Million
Q1 2020

May 15, 2020

SELL
$13.06 - $21.24 $10,448 - $16,992
-800 Reduced 0.07%
1,165,473 $16.8 Million
Q4 2019

Feb 14, 2020

SELL
$17.29 - $21.74 $411,813 - $517,803
-23,818 Reduced 2.0%
1,166,273 $23 Million
Q3 2019

Nov 14, 2019

SELL
$19.51 - $24.28 $286,348 - $356,357
-14,677 Reduced 1.22%
1,190,091 $23.2 Million
Q2 2019

Aug 14, 2019

SELL
$21.47 - $37.33 $1.53 Million - $2.66 Million
-71,180 Reduced 5.58%
1,204,768 $0
Q1 2019

May 15, 2019

BUY
$28.4 - $36.49 $283,403 - $364,133
9,979 Added 0.79%
1,275,948 $46.6 Million
Q4 2018

Feb 14, 2019

SELL
$27.94 - $44.61 $58,841 - $93,948
-2,106 Reduced 0.17%
1,265,969 $37.4 Million
Q3 2018

Nov 14, 2018

BUY
$38.6 - $46.12 $1,930 - $2,306
50 Added 0.0%
1,268,075 $53.8 Million
Q2 2018

Aug 14, 2018

SELL
$40.56 - $51.36 $825,882 - $1.05 Million
-20,362 Reduced 1.58%
1,268,025 $52.2 Million
Q1 2018

May 15, 2018

BUY
$53.61 - $67.26 $1,608 - $2,017
30 Added 0.0%
1,288,387 $74.7 Million
Q4 2017

Feb 14, 2018

SELL
$47.69 - $55.39 $19,123 - $22,211
-401 Reduced 0.03%
1,288,357 $70.5 Million
Q3 2017

Nov 14, 2017

SELL
$49.16 - $54.45 $231,248 - $256,132
-4,704 Reduced 0.36%
1,288,758 $65.5 Million
Q2 2017

Aug 14, 2017

BUY
N/A
1,293,462
1,293,462 $75 Million

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.73B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Clearbridge Investments, LLC Portfolio

Follow Clearbridge Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clearbridge Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clearbridge Investments, LLC with notifications on news.